image description

Tag: Lucin

New York City Walk Kick-off Scored High — Together

Aug. 8, 2017 The New York City Area lupus community came together full force to get the Lupus Research Alliance October 14th Walk with Us to Cure Lupus off to a running start. The fabulous Advancing Lupus Care Through Vital Medical Research event held at iHeart Media headquarters started with cocktails and hors d’oeuvres followed […] Read More

Championing Patient Power in Lupus

January 24, 2024 Dr. Stacie Bell came to LRA’s clinical research affiliate Lupus Therapeutics (LT) one year ago to help fulfill the vision of an entire community united to triumph over a complex and confounding disease.  She joined determined to work with the researchers, clinicians, biopharmaceutical companies, and most importantly the people with lupus and […] Read More

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] Read More

Lupus Research Alliance LuCIN Clinical Trials Network Launches Inaugural Studies

NEW YORK, NY. October 31, 2017 — The Lupus Research Alliance today announced the first clinical trials to be conducted through its Lupus Clinical Investigators Network (LuCIN) aimed at discovering new treatments for the millions of people around the globe living with lupus. Recognizing the limited treatments for lupus, LuCIN was organized, managed and is […] Read More

NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

August 31, 2022 We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food […] Read More

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

LRA Brings Encouraging News from European Rheumatology Meeting

June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] Read More

2017: A Year of Great Triumph for Lupus

Nov. 28, 2017. Thanks to you, the Lupus Research Alliance continues to make game-changing gains in advancing the basic understanding of lupus … while giving hope to millions of people that a potential cure is within reach. We Invested in Innovative Research The Lupus Research Alliance gave 19 scientists the means to bring their ideas […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates